Precision cancer tests encompass imaging and in vitro diagnostic (IVD) products and procedures that directly detect malignancies in patient samples or in the patients themselves.?

According to this study, over the next five years the Precision Cancer Diagnostic Tests market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019. In particular, this report presents the global revenue market share of key companies in Precision Cancer Diagnostic Tests business, shared in Chapter 3.

This report presents a comprehensive overview, market shares and growth opportunities of Precision Cancer Diagnostic Tests market by product type, application, key companies and key regions.

This study considers the Precision Cancer Diagnostic Tests value generated from the sales of the following segments:

Segmentation by product type: breakdown data from 2014 to 2019 in Section 2.3; and forecast to 2024 in section 10.7.
Imaging
Molecular
Tumor Marker Immunoassays
POC Colon Cancer Tests
Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 10.8.
Hospital
Clinic
Other

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
Abbott Laboratories
Agilent Technologies, Inc.
Becton Dickinson and Company
Bio-Rad Laboratories, Inc.
Biocartis N.V.
Biocept, Inc.
bioMerieux SA
Canon Medical Systems Corporation
Cynvenio Biosystems, Inc.
Danaher Corporation
Epigenomics AG
Exosome Diagnostics, Inc.
Foundation Medicine, Inc.
General Electric Company
Genomic Health, Inc.
Hologic, Inc.
Illumina, Inc.
Menarini Silicon Biosystems SpA
Myriad Genetics, Inc.
NanoString Technologies, Inc.
Ortho Clinical Diagnostics
QIAGEN N.V.
Randox Laboratories Ltd.
Roche Holding AG
Royal Philips N.V.
Siemens AG
Thermo Fisher Scientific
Vela Diagnostics

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key players and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives
To study and analyze the global Precision Cancer Diagnostic Tests market size by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
To understand the structure of Precision Cancer Diagnostic Tests market by identifying its various subsegments.
Focuses on the key global Precision Cancer Diagnostic Tests players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Precision Cancer Diagnostic Tests with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the size of Precision Cancer Diagnostic Tests submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.